Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer.
Francesca ParisiMaria Grazia RazetiEva BlondeauxLuca AreccoMarta PerachinoMarco TagliamentoAlessia LevaggiPiero FregattiFrancesca PoggioMatteo LambertiniPublished in: Clinical Medicine Insights. Oncology (2020)
Breast cancer is the most frequent malignancy diagnosed in premenopausal women. In this age group, breast tumors tend to be diagnosed at more advanced stages and to harbor more aggressive biological features. In addition, specific age-related issues including genetic counseling, fertility preservation, impact on social and couple relationships, working life, and management of long-term side effects should be considered highly relevant when managing early breast cancer in premenopausal women. Therefore, the care of these patients is particularly complex and a multidisciplinary approach is mandatory. The present review summarizes the current state of art in the adjuvant systemic treatment of premenopausal women with early breast cancer focusing on the optimal chemotherapy, endocrine therapy, and targeted therapy approaches in this specific patient population.
Keyphrases
- early breast cancer
- healthcare
- end stage renal disease
- early stage
- polycystic ovary syndrome
- breast cancer risk
- ejection fraction
- chronic kidney disease
- quality improvement
- postmenopausal women
- palliative care
- hiv infected
- type diabetes
- smoking cessation
- gene expression
- antiretroviral therapy
- metabolic syndrome
- young adults
- squamous cell carcinoma
- pregnant women
- patient reported outcomes
- replacement therapy
- bone marrow
- mesenchymal stem cells
- patient reported
- combination therapy
- chronic pain
- men who have sex with men